New horizons on the application of B-cell targeted therapy for pediatric IgA nephropathy
10.3760/cma.j.issn.1673-4912.2025.06.002
- VernacularTitle:B细胞靶向治疗在儿童IgA肾病应用的新视界
- Author:
Qian SHEN
1
Author Information
1. 复旦大学附属儿科医院肾脏科 上海市肾脏发育和儿童肾脏病研究中心 肾脏疾病全国重点实验室，上海 201102
- Publication Type:Journal Article
- Keywords:
IgA nephropathy;
Children;
B-cell;
Targeted therapy
- From:
Chinese Pediatric Emergency Medicine
2025;32(6):406-412
- CountryChina
- Language:Chinese
-
Abstract:
IgA nephropathy（IgAN）is one of the most common primary glomerular diseases and a leading cause of chronic kidney disease and end stage kidney disease worldwide both in children and adults.B cells and their related factors，including B-cell activating factor（BAFF）and a proliferation-inducing ligand（APRIL），play critical roles in the pathogenesis of IgAN.In recent years，significant advancements have been achieved in drug development targeting B cell depletion and the BAFF/APRIL signaling pathways.The advancement of clinical trials of B-cell and cytokine-targeted drugs such as Rituximab，Felzartamab，Sibeprenlimab，Zigakibart，Atacicept，Telitacicept and Povetacicept has also brought new directions for the further optimization of the treatment regimens for children with IgA nephropathy.
